AstraZeneca CEO Pascal Soriot faces scrutiny over rejecting a deal, maintaining a long-term R&D strategy over short-term acquisitions while targeting $80bn revenue by 2030.
AstraZeneca CEO Pascal Soriot urges Western pharma to accelerate innovation against Chinese rivals, likening the challenge to the automotive industry's EV shift. Despite a recent trial failure, the co
AstraZeneca has agreed to pay CSPC Pharmaceutical Group up to $18.5 billion for eight drug development programs targeting weight loss and Type 2 diabetes, including a $1.2 billion upfront payment.
ChemBrief